Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cohort A: PARP Inhibitor-Naïve Platinum-Resistant Ovarian Cancer Treatment Cohort With TSR-042, Bevacizumab, and Niraparib

NCT05751629 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT05751629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05751629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cohort A: PARP Inhibitor-Naïve Platinum-Resistant Ovarian Cancer Treatment Cohort With TSR-042, Bevacizumab, and Niraparib
Lead sponsor
Tesaro, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2018
Completion date
April 1, 2022
Enrollment
41 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasm